ProCE Banner Activity

SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC

Slideset Download
Conference Coverage
No significant difference in OS noted, but patients in treated population who received SIRT experienced higher ORR and fewer AEs/serious AEs vs those who received sorafenib.

Released: June 07, 2017

Expiration: June 06, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology